FDA Brief

Warning letters Drugs

FDA warning letter to

Honest Globe, Inc.

High riskIssued Mar 15, 2021Posted Mar 22, 2021Division of Pharmaceutical Quality Operations IV

FDA cited Honest Globe for manufacturing-quality failures and for selling unapproved CBD pain-relief drugs.

What happened

FDA inspected Honest Globe’s Santa Ana drug manufacturing facility from October 4 to 8, 2019, and reviewed the company’s website at www.elixicure.com. FDA found current good manufacturing practice (CGMP) violations in quality-unit oversight, batch records, and process validation, and found the ELIXICURE CBD pain-relief products marketed as unapproved new drugs and as misbranded (labeling-violation) drugs.

What FDA found

  1. The quality unit released batches after out-of-specification camphor results by retesting until passing, without investigating, and production staff also performed quality approvals.

    21 CFR 211.22(a) and 211.22(d)
  2. Batch production records did not document key manufacturing details such as weights, mixing times and speeds, temperatures, hold times, in-process testing, and filling-machine settings.

    21 CFR 211.188(b)
  3. The firm lacked written production and process control procedures and had not qualified equipment or validated manufacturing processes, including process performance qualification.

    21 CFR 211.100(a)
  4. The CBD pain-relief products were unapproved new drugs sold without an approved application and did not meet OTC marketing requirements under section 505G.

    FD&C Act sections 505(a), 301(d); 21 U.S.C. 355(a), 331(d)
  5. The products were misbranded drugs.

    FD&C Act sections 502(a), 502(ee), 301(a); 21 U.S.C. 352(a), 352(ee), 331(a)
  6. FDA said CBD cannot be a safe and suitable inactive ingredient and the products did not meet 21 CFR 330.1(e) if CBD was intended as inactive.

    21 CFR 330.1(e); FD&C Act section 505G

What FDA wants

FDA tells the company to audit released batches and OOS results, assess component specifications and quality-unit authority, revise master production records and documentation practices, and provide equipment qualification and process performance qualification plans. The provided letter does not state a response deadline.

Who should pay attention

  • CBD topical drug brands
  • OTC drug contract manufacturers
  • quality teams at small drug manufacturers

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  3. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  4. Penn Herb Company, Ltd.

    FDA warned Penn Herb Company over CGMP violations and an undeclared tree-nut allergen in three dietary supplements.

    High risk